Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Provided By GlobeNewswire
Last update: Jan 6, 2025
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025
Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones
Read more at globenewswire.comNASDAQ:FBIO (6/16/2025, 4:04:07 PM)
1.84
-0.01 (-0.54%)
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP
NASDAQ:FBIOP (6/16/2025, 4:00:47 PM)
8.68
-0.34 (-3.77%)
Find more stocks in the Stock Screener
